Abstract: The present invention provides an anti-PAC1 monoclonal antibody capable of recognizing a PAC1 having a native structure, a PAC1 activity regulator (in particular, activity inhibitor) containing the antibody, a prophylactic/therapeutic agent for a disease associated with accentuation of a bioactivity of PAC1, containing the antibody, a diagnostic reagent for a disease associated with an abnormality of PAC1 activity, containing the antibody, and a screening method for a substance that regulates the expression of PAC1, using the antibody and a PAC1-expressing cell.
Type:
Application
Filed:
August 7, 2007
Publication date:
May 6, 2010
Applicants:
Kyoto University, Takeda Pharmacetical Company Limited
Abstract: The present invention is directed to a class of cyclohexene derivatives bearing sulfamoyl and ester groups which have an inhibitory activity on nitric oxide (NO) production and cytokine production, and are useful as an agent for the prophylaxis and/or treatment of diseases such as, cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, and septic shock.
Type:
Grant
Filed:
March 31, 2005
Date of Patent:
August 26, 2008
Assignee:
Takeda Pharmacetical Company Limited
Inventors:
Norikazu Tamura, Takashi Ichikawa, Masayuki Ii